Tian Ying-Xuan, Yang Shuan-Ying, Nan Yan-Dong, Zhang Wei, Zhou Bin, Bu Li-Na, Huo Shu-Fen, Yu Jie-Kai, Zheng Shu
Department of Respiratory Medicine, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an 710004, China.
Zhonghua Yi Xue Za Zhi. 2008 Jan 15;88(3):145-8.
To screen biomarkers for classification in lung adenocarcinoma and lung squamous carcinoma by using laser capture microdissection (LCM) and surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and support vector machine (SVM).
Six specimens of lung adenocarcinoma tissues and seven specimens of lung squamous carcinoma tissues obtained during operation were made into frozen sections and stained by improved H-E solution. About 1.2 x 10(5) of homogeneous adenocarcinoma cells and 1.4 x 10(5) of homogeneous lung squamous carcinoma cells were collected using LCM. Then SELDI profiles based on PBS II(+)SELDI-TOF-MS (IMAC protein chip) and the data were analyzed by support vector machine (SVM).
Eighty seven differential protein peaks were found and top ten of them were identified as candidate biomarkers. The expression levels of 6 proteins among them with the molecular weights of 3333, 3592, 3848, 5036, 5191, and 5211 respectively in the lung squamous cancer tissues were weaker than those in the adenocarcinoma tissues, and the expression levels of 4 proteins with the molecular weights of 2505, 4004, 4847, and 11 412 in the lung squamous carcinoma tissues were stronger than those in the adenocarcinoma tissues. The expression of the protein with the molecular weight of 4847 in the squamous cancer was significantly stronger than that in the adenocarcinoma (p + 0.032). A discriminatory pattern consisting of 3 proteins with the molecular weights of 4847, 11 412, and 3592 was established with a sensitivity of 100% and a specificity of 100% respectively in separating adenocarcinoma from squamous carcinoma.
There is a difference in protein component between adenocarcinoma and squamous carcinoma. LCM combined with SELDI-TOF-MS help screen a biomarker pattern to distinguish lung adenocarcinoma from lung squamous carcinoma with high sensitivity and specificity.
运用激光捕获显微切割技术(LCM)、表面增强激光解吸电离飞行时间质谱技术(SELDI-TOF-MS)以及支持向量机(SVM)筛选肺腺癌和肺鳞癌分类的生物标志物。
将手术中获取的6例肺腺癌组织标本和7例肺鳞癌组织标本制成冰冻切片,用改良苏木精-伊红(H-E)溶液染色。运用LCM收集约1.2×10⁵个均匀的腺癌细胞和1.4×10⁵个均匀的肺鳞癌细胞。然后基于PBS II(+)SELDI-TOF-MS(IMAC蛋白芯片)获取SELDI图谱,并通过支持向量机(SVM)分析数据。
发现87个差异蛋白峰,其中前10个被确定为候选生物标志物。其中分子量分别为3333、3592、3848、5036、5191和5211的6种蛋白在肺鳞癌组织中的表达水平低于腺癌组织,分子量为2505、4004、4847和11412的4种蛋白在肺鳞癌组织中的表达水平高于腺癌组织。分子量为4847的蛋白在鳞癌中的表达明显高于腺癌(p<0.032)。建立了由分子量为4847、11412和3592的3种蛋白组成的鉴别模式,在区分腺癌和鳞癌时灵敏度和特异度分别为100%。
腺癌和鳞癌的蛋白质成分存在差异。LCM联合SELDI-TOF-MS有助于筛选出一种具有高灵敏度和特异度的生物标志物模式来区分肺腺癌和肺鳞癌。